Controls extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to…. ANDA 40103, held by Aiping Pharmaceutical. Benztropine Mesylate.
As of Nov 22, 2026, ANDA 40103 (Benztropine Mesylate), held by Aiping Pharmaceutical, was first approved by FDA on Dec 12, 1996, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 12, 1996 | Original application | Approved | None posted |
| Benztropine Mesylate0.5MG · tablet;oral | Benztropine Mesylate | Rx |
| Benztropine Mesylate1MG · tablet;oral | Benztropine Mesylate | Rx |
| Benztropine Mesylate2MG · tablet;oral | Benztropine Mesylate | Rx |
| Aug 2, 2024 | Supplement 24Manufacturing | Approved | None posted |
| Feb 10, 2005 | Supplement 6Labeling | Approved | None posted |
| Nov 12, 2002 | Supplement 2Labeling | Approved | None posted |
| Mar 6, 1998 | Supplement 1Labeling | Approved | None posted |
| Dec 12, 1996 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters